More than 100 companies reported better-than-expected results in pharma

Under the background of frequent "thunderstorms" in Baima stock market, companies whose performance exceeded expectations by a large margin aroused market attention. Data show that more than 100 of the more than 2,000 listed companies that have disclosed their reported results have increased significantly, exceeding market expectations. Pharmaceutical, electronic components, communications and other industries have become the hotspot for the birth of companies reporting better than expected performance. According to the Wind data of 113 companies, which have made outstanding performance as of August 13, of the 2259 listed companies that have reported and forecasted their mid-term performance, 113 companies have significantly exceeded market expectations. Among them, Dongfangsheng, Dongfangsheng Cable, Jianlang Hardware and many other listed companies have achieved more than double growth in net profit while exceeding the expected performance of the market. Taking Dongfang Cable as an example, in the first half of this year, the company realized business income of 1.490 billion yuan, an increase of 7.45% over the same period last year, and realized net profit of 180 million yuan belonging to shareholders of listed companies, an increase of 220.09% over the same period last year, which exceeded market expectations. In the first half of this year, many industries exceeded market expectations, and related listed companies reported outstanding results. With Shengnong Development as an example, because the prosperity of the poultry chain exceeded expectations in the first half of the year, the company's chicken business profitability increased substantially, thus driving the company to achieve business income of 6.554 billion yuan, an increase of 29.27% year on year, and realized net profit of 1.653 billion yuan belonging to shareholders of listed companies, an increase of 39.34 billion yuan year on year. It is precious that many listed companies still achieve counter-trend growth against the background of unfavorable industry development. Taking Linglong tire as an example, in the first half of this year, the domestic automobile production and sales sluggish background, the company's tire production and sales adverse growth, driving the company to achieve business income of 831 billion yuan, an increase of 14.74% year on year; to achieve a net profit of 725 million yuan belonging to shareholders of listed companies, an increase of 38.47% year on year. According to the research report issued by China Merchants Securities, exquisite tires can achieve the negative growth of tire production and sales in the first half of the year and the performance of the mid-term report exceeded expectations, mainly due to the strong performance of the company in the retail market, especially the overseas retail sales represented by the Thai factories exceeded expectations. At the same time, the company continues to make breakthroughs in the supporting market. With the advantage of cost-effective, it quickly penetrates the supporting business of Ford, Volkswagen, Geely and other well-known mainframe factories at home and abroad. The new business has smoothed the decline of the domestic supporting market.
In many industries, medicine, electronic components, communications, machinery and other industries have become hot spots for the birth of listed companies whose performance exceeds expectations. Among them, the pharmaceutical industry has become the big winner of Zhongbao's performance exceeding expectations. There are 18 listed companies such as Antu Biology, Liuyao Stock, Jinyu Medical, Tongce Medical, Dongcheng Pharmaceutical, Beilu Pharmaceutical, Renewal Biochemical, Tiantan Biology, etc. whose Zhongbao performance exceeds market expectations. Taking Jinyu Medical Company as an example, in the first half of the year, the company realized business income of 2.543 billion yuan, an increase of 20.26% over the previous year, and realized net profit of 172 million yuan belonging to shareholders of listed companies, an increase of 78.92% over the previous year, which exceeded market expectations. As of August 13, 54 pharmaceutical listed companies have disclosed semi-annual reports or semi-annual performance reports, 45 of which have achieved a year-on-year increase in net profit. Among them, the net profit of 11 companies increased by more than 50% year-on-year. Another 86 pharmaceutical listed companies disclosed medium-term performance forecasts, and 60 expected net profits to grow year-on-year in the first half of the year. At the same time, influenced by many favorable factors, such as infrastructure repair board, environmental protection policy tightening, equipment renewal and so on, the sustained recovery of downstream demand in construction machinery industry drives the continuous growth of excavator sales, thus driving the performance of many listed companies in machinery industry to exceed expectations. Taking Sany Heavy Industry as an example, the company expects to achieve net profit of 6.5 billion to 7 billion yuan attributable to shareholders of Listed Companies in the first half of the year, an increase of 91.82% to 106.58%. In addition, although Fuling mustard pickle performance explosion caused market concern. Among many industries, pharmaceutical, electronic components, communications, machinery and other industries have become the hot ground for the birth of listed companies whose performance exceeded expectations. Among them, the pharmaceutical industry has become a big winner of Zhongbao's performance exceeding expectations.
Looking for chemical products? Let suppliers reach out to you!
2026-05-30
-
Life Science Ingredients Industry Overview
This issue offers a deep exploration of the evolving pharmaceutical and nutrition landscape, combining data, analysis, and insight to reveal key industry shifts and emerging directions. Support online permanent download.Published in: Nov. 2025
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Pharma Quality Excellence Awards 2026 - Celebration and Conclusion
-
Pharma Quality Reimagined: Highlights from the 6th Annual Pharma GMP & Quality Management 2026
-
From Feedmill to Food System: VIV Europe 2026 Addresses the Industry's Most Critical Challenges
-
Beyond Compliance: Building Quality Maturity
-
Is the class solidified? From Biotech to Pharma
-
The IPO of the Largest Domestic Metronidazole API Manufacturer has Passed the Meeting
-
Progesterone Market Potential is Huge
-
China丨Norsyn received IPO approval from China Securities Regulatory Commission
-
Project丨13,600 tons of pesticide technical and intermediate projects to be implemented in Hubei, China
-
PharmaReg AfriSummit
Recommend Reading
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
J&J to Spin Off Orthopedics Business, Raises 2025 Forecast
-
Cost Support, High Inventory Levels—Natural Rubber Market Prices Fluctuate and Consolidate
-
China Energy Group Appoints Xu Xinfu as Board Director and Deputy Party Secretary Ranks 84th in Fortune Global 500
-
September Phosphate Market Trends Rise Initially, Then Fall
-
Cost Benefits Drive a Noticeable Price Increase in Polyester Staple Fiber
-
Mitsubishi Chemical to End Toner Resin Production by March 2026 Plans 400 Billion Yen Asset Exit